Pfizer joins series A round for Ablexis as drugs companies seek mice to test
Pfizer Venture Investments, the top 10-ranked healthcare corporate venturing division of US-listed Pfizer, has joined the $12m series A round for the maker of laboratory mice.
Ablexis, a US-based developer of its proprietory AlivaMab Mouse used as a transgenic platform for human drug discovery raised the series A in a round led by US venture capital firm Third Rock Ventures.
So-called transgenic mice have been targeted by pharmaceutical companies with biotechnology firm Amgen buying Abgenix’s XenoMouse technology while Bristol-Myers…
